Literature DB >> 3081470

Gene products of the HLA-D region in normal and malignant tissues of nonlymphoid origin.

P Natali, A Bigotti, R Cavalieri, M R Nicotra, R Tecce, D Manfredi, Y X Chen, L M Nadler, S Ferrone.   

Abstract

Indirect immunofluorescence staining with monoclonal antibodies has shown a differential distribution of HLA-DR, DQ, and DP antigens in normal tissues of nonlymphoid origin. The distribution of HLA-DP antigens is similar to that of HLA-DR antigens, while that of HLA-DQ antigens is more restricted. Malignant transformation of cells of nonlymphoid origin may be associated with the appearance of the gene products of the HLA-D region. HLA-DR antigens appear more frequently than the other two types of HLA class II antigens and HLA-DP antigens more frequently than HLA-DQ antigens. Differential expression of the gene products of the HLA-D region was also found in autologous metastases removed from different anatomic sites from patients with melanoma. The HLA class II phenotype of surgically removed malignant lesions did not correlate with the degree of differentiation of tumor cells and/or with the expression and/or cellular distribution of HLA class I antigens. Furthermore, in melanoma lesions, no relationship was found between the HLA class II phenotype and the expression of 3 membrane bound and 1 cytoplasmic melanoma associated antigen recognized by monoclonal antibodies. The functional significance and the practical implications of the differential expression of the gene products of the HLA-D region by tumor cells are discussed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3081470     DOI: 10.1016/0198-8859(86)90028-5

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  9 in total

1.  Antigen expression of metastasizing and non-metastasizing human melanoma cells xenografted into nude mice.

Authors:  G N Van Muijen; L M Cornelissen; C F Jansen; C G Figdor; J P Johnson; E B Bröcker; D J Ruiter
Journal:  Clin Exp Metastasis       Date:  1991 May-Jun       Impact factor: 5.150

2.  Analysis of RNA transcripts for HLA class II genes in human small intestinal biopsies.

Authors:  B A Volk; D A Brenner; M F Kagnoff
Journal:  Gut       Date:  1989-09       Impact factor: 23.059

3.  Expression of MHC class II antigens (HLA-DR, -DP, and -DQ) on human gastric epithelium.

Authors:  N Ishii; M Chiba; M Iizuka; H Watanabe; T Ishioka; O Masamune
Journal:  Gastroenterol Jpn       Date:  1992-02

4.  Anomalous expression of HLA class II molecules on keratinocytes and fibroblasts in hypertrophic scars consequent to thermal injury.

Authors:  C Castagnoli; M Stella; G Magliacani; S T Alasia; P Richiardi
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

5.  Gamma-interferon-inducible lysosomal thiol reductase is upregulated in human melanoma.

Authors:  Jennifer Nguyen; Richard Bernert; Kevin In; Paul Kang; Noemi Sebastiao; Chengcheng Hu; K Taraszka Hastings
Journal:  Melanoma Res       Date:  2016-04       Impact factor: 3.599

6.  HLA-D Antigen Expression and Langerhans' Cell Infiltrates in Thyroid Tumors.

Authors:  Simon L. Raphael; Sylvia L. Asa
Journal:  Endocr Pathol       Date:  1995       Impact factor: 3.943

7.  Expression of MHC class II, interleukin 2 receptor and CD45 antigens on tumour-associated T lymphocytes in colonic carcinoma.

Authors:  M N Norazmi; A W Hohmann; J M Skinner; J Bradley
Journal:  Br J Cancer       Date:  1989-11       Impact factor: 7.640

8.  Lacking prognostic significance of beta 2-microglobulin, MHC class I and class II antigen expression in breast carcinomas.

Authors:  H O Wintzer; M Benzing; S von Kleist
Journal:  Br J Cancer       Date:  1990-08       Impact factor: 7.640

9.  Prognostic significance of major histocompatibility complex class II antigens (HLA-DR) in normal colonic mucosa, tubulovillous adenoma, and invasive colonic carcinoma.

Authors:  Demetrio Tamiolakis; Sylvia Nicolaidou; Sophia Bolioti; Anna Tzilivaki
Journal:  Ann Saudi Med       Date:  2006 Mar-Apr       Impact factor: 1.526

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.